Laurus Labs Ltd
LAURUSLABS
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.90 | 4.90 | 0.65% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 32.71 | 3.96 | 0.99% |
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Reliance, Wipro, Jubilant FoodWorks, Crompton Greaves hit 52-week lows
2 days ago•Business Standard
RIL, Tata Consumer, Laurus Labs: These 14 popular shares are trading at 52-week lows; which stock to buy?
1 week ago•Business Today
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
1 week ago•Business Standard
Recent EventsAll events
Shareholders meeting
Laurus Labs Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results along with scrutinizer report.. | Download
Laurus Labs Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results along with scrutinizer report.. | Download
Cash Dividend
Interim • Div/Share: ₹ 0.8
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant